International Journal of Infectious Diseases
Volume 14, Issue 9 , Pages e810-e814 , September 2010

Prevalence of human papillomavirus genotypes in HIV-1-infected women in Seattle, USA and Nairobi, Kenya: results from the Women's HIV Interdisciplinary Network (WHIN)

  • Amneris E. Luque

      Affiliations

    • Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 689, 601 Elmwood Avenue, Rochester, NY 14642, USA
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jane Hitti

      Affiliations

    • Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA
    • ,
  • Christina Mwachari

      Affiliations

    • Center for Respiratory Disease Research, Kenya Medical Research Institute, Nairobi, Kenya
    • ,
  • Christopher Lane

      Affiliations

    • Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 689, 601 Elmwood Avenue, Rochester, NY 14642, USA
    • ,
  • Susan Messing

      Affiliations

    • Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    • ,
  • Susan E. Cohn

      Affiliations

    • Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 689, 601 Elmwood Avenue, Rochester, NY 14642, USA
    • ,
  • David Adler

      Affiliations

    • Departments of Emergency Medicine and Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    • ,
  • Robert Rose

      Affiliations

    • Infectious Diseases Division, Department of Medicine, University of Rochester School of Medicine and Dentistry, Box 689, 601 Elmwood Avenue, Rochester, NY 14642, USA
    • Department of Microbiology and Immunology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    • ,
  • Robert Coombs

      Affiliations

    • Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA

Received 2 December 2009 ,Accepted 1 March 2010.

References 

  1. Reisinger KS, Block S, Lazcano-Ponce E, Samakoses R, Esser M, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201–209
  2. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007;177:469–479
  3. Paavonen J, Jenkins D, Bosch XF, Naud P, Salmerón J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170
  4. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1–24
  5. Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulvar and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693–1702
  6. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88:63–73
  7. Munoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278–285
  8. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–632
  9. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J Clin Virol. 2002;25(Suppl 3):S89–97
  10. Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 HPV types from L1 consensus PCR products using a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36:3020–3027
  11. Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC, et al. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis. 2006;194:428–434
  12. Clifford GM, Goncalves MA, Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20:2337–2344
  13. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, Stringer JSA, et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer. 2007;96:1480–1483
  14. La Ruche G, You B, Mensah-Ado I, Bergeron C, Montcho C, Ramon R, et al. Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia–neoplasia in African women. Int J Cancer. 1998;76:480–486
  15. Moodley JR, Hoffman M, Carrara H, Allan BR, Cooper DD, Rosenberg L, et al. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case–control study. BMC Cancer. 2006;6:135
  16. Ng’andwe C, Lowe JJ, Richards PJ, Hause L, Wood C, Angeletti PC. The distribution of sexually-transmitted human papillomaviruses in HIV positive and negative patients in Zambia, Africa. BMC Infect Dis. 2007;7:77
  17. Parham GP, Sahasrabuddhe VV, Mwanahamuntu MH, Shepherd BE, Hicks ML, Stringer EM, et al. Prevalence and predictors of squamous intraepithelial lesions of the cervix in HIV-infected women in Lusaka, Zambia. Gynecol Oncol. 2006;103:1017–1022
  18. Blossom DB, Beigi RH, Farrell JJ, Mackay W, Qadadri B, Brown DR, et al. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. J Med Virol. 2007;79:758–765
  19. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, Vallès X, Ouedraogo A, Konate I, et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer. 2006;95:355–362
  20. Baay MF, Kjetland EF, Ndhlovu PD, Deschoolmeester V, Mduluza T, Gomo E, et al. Human papillomavirus in a rural community in Zimbabwe: the impact of HIV co-infection on HPV genotype distribution. J Med Virol. 2004;73:481–485
  21. Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, et al. Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst. 2003;95:1062–1071
  22. Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries—key challenges and issues. N Engl J Med. 2007;356:1908–1910
  23. Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109:418–424

☆ Presented in part at the International AIDS Conference in Mexico City, Mexico, August 2008 (abstract THAC0306).

PII: S1201-9712(10)02410-0

doi: 10.1016/j.ijid.2010.03.016

International Journal of Infectious Diseases
Volume 14, Issue 9 , Pages e810-e814 , September 2010

Article Tools